Welcome to our dedicated page for Leap Therapeutics news (Ticker: LPTX), a resource for investors and traders seeking the latest updates and insights on Leap Therapeutics stock.
Leap Therapeutics, Inc. (Nasdaq: LPTX) is a pioneering clinical-stage biopharmaceutical company focused on developing novel targeted antibody therapies for cancer treatment. Headquartered in Cambridge, Massachusetts, Leap Therapeutics aims to discover and advance transformative cancer treatments by targeting tumor-promoting pathways, cancer-specific cell surface molecules, and activating the immune system against cancer cells.
The company's lead program, DKN-01, is a humanized monoclonal antibody that targets Dickkopf-related protein 1 (DKK1). This promising candidate is in clinical trials for treating esophagogastric, gynecologic, and colorectal cancers. Another key program, FL-301, targets Claudin18.2-expressing cells and is being developed for gastric and pancreatic cancer treatments. Leap Therapeutics also has two preclinical antibody programs, FL-302 and FL-501, which are advancing toward developing innovative cancer therapies.
Operating as a single segment dedicated to oncology, Leap Therapeutics has established several strategic collaborations to enhance its development pipeline, including a clinical collaboration with BeiGene for the DisTinGuish trial and partnerships with NovaRock Biotherapeutics and Adimab. The company's dedication to advancing targeted and immuno-oncology therapeutics underscores its commitment to addressing unmet needs in cancer treatment. Leap's research and development activities continue to make significant progress, with ongoing clinical trials and new data demonstrating the potential efficacy and safety of its therapeutic candidates.
In recent news, Leap Therapeutics announced the completion of enrollment in the randomized controlled Part C of the DisTinGuish study, evaluating DKN-01 in combination with tislelizumab and chemotherapy for advanced gastroesophageal junction and gastric cancer. Additionally, the company reported financial results for the first quarter of 2024, highlighting a successful $40 million financing that extends its cash runway into the second quarter of 2026. This funding will support the expansion and continued execution of the DKN-01 development program, including the expansion of the randomized controlled Part B of the DeFianCe study in second-line colorectal cancer patients.
For more information about Leap Therapeutics, visit www.leaptx.com or view their public filings with the SEC available via EDGAR at www.sec.gov or www.investors.leaptx.com.
Leap Therapeutics, Inc. (NASDAQ: LPTX) announced its presentation of long-term follow-up data from Part A of the DisTinGuish study at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for June 2-6, 2023, in Chicago, IL. This Phase 2 clinical trial evaluates the efficacy of DKN-01, an anti-DICKKOPF-1 antibody, in combination with tislelizumab and chemotherapy for patients with advanced gastroesophageal adenocarcinoma (GEA). The presentation will occur on June 5, 2023, at 11:30 a.m. ET, featuring Samuel J. Klempner from Harvard Medical School. The study aims to assess the safety and effectiveness of DKN-01 in various patient groups, as Leap continues to develop targeted cancer therapies.
FAQ
What is the current stock price of Leap Therapeutics (LPTX)?
What is the market cap of Leap Therapeutics (LPTX)?
What does Leap Therapeutics, Inc. specialize in?
What is DKN-01?
What are the latest developments in Leap Therapeutics' clinical trials?
Who are Leap Therapeutics' collaboration partners?
What are the financial highlights from Leap Therapeutics' latest quarter?
Where is Leap Therapeutics headquartered?
What is FL-301?
How does Leap Therapeutics plan to use the recent $40 million financing?
What are Leap Therapeutics' preclinical programs?
How can one access Leap Therapeutics' public filings?
